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1. INTRODUCTION {#cam42163-sec-0001}
===============

Prostate cancer is the second most common cancer and the fourth leading cause of cancer death in men, worldwide.[1](#cam42163-bib-0001){ref-type="ref"} Most early stage prostate cancers tend to develop slowly and show an indolent clinical course. However, some prostate cancers display aggressive behavior and metastasize to other organs.[2](#cam42163-bib-0002){ref-type="ref"} While localized prostate cancer can be well controlled by active surveillance, radical prostatectomy (RP), or radiotherapy, metastatic tumors remain a lethal disease. Therefore, identification of key molecules and accurate prediction of patient prognosis are particularly important for prognostic and therapeutic purposes.

Recent evidence indicates that epithelial‐to‐mesenchymal transition (EMT) is a critical step for cancer progression. During EMT, polarized epithelial cells alter cell adhesion molecules and generate a new microenvironment, acquiring the aggressive behavior of metastatic competence, such as stem cell‐like features and treatment resistance.[3](#cam42163-bib-0003){ref-type="ref"} It is believed that the dysfunction of cell adhesion molecules, such as cadherins and integrins, is involved in cancer progression, based on the correlation of their expressions and tumor stage, metastasis, as well survival.[4](#cam42163-bib-0004){ref-type="ref"}, [5](#cam42163-bib-0005){ref-type="ref"}

Given the important role of EMT in carcinogenesis, we hypothesized that genetic variants in cell adhesion molecules might influence the prognosis of prostate cancer. Therefore, we conducted a two‐stage study to investigate the impact of single‐nucleotide polymorphisms (SNPs) in eight cancer‐related cell adhesion molecules on the biochemical recurrence (BCR) in patients with localized prostate cancer after RP.

2. MATERIALS AND METHODS {#cam42163-sec-0002}
========================

2.1. Patient recruitment and data collection {#cam42163-sec-0003}
--------------------------------------------

A total of 643 patients, with histopathologically confirmed prostate cancer, that underwent RP were recruited from three Taiwan medical centers: Kaohsiung Medical University Hospital, Kaohsiung Veterans General Hospital, and National Taiwan University Hospital, as described previously.[6](#cam42163-bib-0006){ref-type="ref"} A two‐stage approach was applied to evaluate the effect of genetic variants in cell adhesion pathway genes on patient prognosis. Therefore, the study population was randomly divided into discovery and replication sets with a 7:3 ratio. The demographic data were collected through in‐person interviews using a structured questionnaire, which intends to identify individuals and/or families probably at‐risk for prostate cancer, and the clinicopathologic information was retrieved from patients' medical records. All participants in the study were unrelated. BCR was defined according to two consecutive prostate‐specific antigen (PSA) measurements of 0.2 ng/mL or more after RP.[7](#cam42163-bib-0007){ref-type="ref"}, [8](#cam42163-bib-0008){ref-type="ref"} BCR‐free survival was defined as the duration from RP to the date of BCR. This study was approved by the institutional review board of Kaohsiung Medical University Hospital, and all participants signed the informed consent form according to institutional guidelines.

2.2. SNP selection and genotyping {#cam42163-sec-0004}
---------------------------------

Several adhesion molecules commonly participate in the cancer metastasis process, including CD276 molecule (CD276), CD6 molecule (CD6), CD8a molecule (CD8A), cadherin 2 (CDH2), claudin 11 (CLDN11), integrin subunit beta 1 (ITGB1), integrin subunit beta 7 (ITGB7), and poliovirus receptor (PVR). We initially selected 25 common tag SNPs in these cell adhesion genes using SNPinfo,[11](#cam42163-bib-0011){ref-type="ref"} based on the following criteria: a minor allele frequency of \> 0.05 in the HapMap CHB (Han Chinese in Beijing) population, a pairwise linkage disequilibrium squared correlation coefficient (*r* ^2^) of \> 0.8, whether they were potentially functional, and a maximum of five tag SNPs per gene. Genomic DNA was extracted from peripheral blood samples using the QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA, USA) according to manufacturer\'s instructions. Genotyping was carried out using Agena Bioscience iPLEX matrix‐assisted laser desorption/ionization time‐of‐flight mass‐spectrometry technology at the National Centre for Genome Medicine, Taiwan, as described previously.[12](#cam42163-bib-0012){ref-type="ref"} The average genotype call rate for these SNPs was 92.6% and the average concordance rate was 99.9% among 35 blind duplicated quality control samples. Any SNP that failed at assay design (*N* = 1), below a genotyping call rate of 80% (*N* = 4), or did not conform to Hardy‐Weinberg equilibrium (*P* \< 0.005, *N* = 2), was removed. Thus, a total of 18 SNPs were included for further analyses.

2.3. Bioinformatics analysis {#cam42163-sec-0005}
----------------------------

The regulatory annotation of the risk SNPs and their proxies (*r* ^2^ ≥ 0.8 in the Asian population from 1000 Genomes Project) was conducted by HaploReg v4.1.[13](#cam42163-bib-0013){ref-type="ref"} Expression quantitative trait loci (eQTL) analysis was performed by using Genotype‐Tissue Expression (GTEx).[14](#cam42163-bib-0014){ref-type="ref"} The prognostic significance of prostate cancer was analyzed using the publicly available GSE70769 microarray dataset.[15](#cam42163-bib-0015){ref-type="ref"}

2.4. Statistical analysis {#cam42163-sec-0006}
-------------------------

All statistical analyses were undertaken with Statistical Package for the Social Sciences software version 19.0.0 (IBM). Kaplan‐Meier analysis with log‐rank test was used to compare survival time between subgroups. Additive, dominant, and recessive genetic models were applied to analyze the prognostic effects of cell adhesion gene SNPs. The hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) were calculated by multivariate Cox regression analyses, which were adjusted for age, PSA at diagnosis, pathologic Gleason score, stage, and surgical margin. The combined HRs and 95% CIs were calculated by random effect models when heterogeneity of between‐set existed; otherwise a fixed effect model was used. All tests were two‐sided, and *P*‐values \< 0.05 were regarded as statistically significant.

3. RESULTS {#cam42163-sec-0007}
==========

The clinicopathologic characteristics of patients in the discovery and replication sets are shown in Table [1](#cam42163-tbl-0001){ref-type="table"}. Most characteristics are comparable between the two sets. One hundred eighty‐four (40.2%) and 90 (48.6%) patients experienced BCR during the median follow‐up times of 54 and 74 months in the discovery and replication sets, respectively.

###### 

Clinicopathologic characteristics of the study populations

  Characteristics                        Discovery         Replication
  -------------------------------------- ----------------- -----------------
  No. of patients                        458               185
  Median age, years (IQR)                66 (61‐70)        66 (61‐70)
  Median PSA at diagnosis, ng/mL (IQR)   11.1 (7.1‐17.5)   11.0 (6.9‐18.7)
  Gleason score, *N* (%)                                   
  2                                      3 (0.7)           2 (1.1)
  4                                      8 (1.8)           5 (2.8)
  5                                      30 (6.6)          13 (7.2)
  6                                      119 (26.3)        52 (28.7)
  7                                      232 (51.2)        83 (45.9)
  8                                      25 (5.5)          8 (4.4)
  9                                      32 (7.1)          17 (9.4)
  10                                     4 (0.9)           1 (0.6)
  Pathologic stage, N (%)                                  
  1                                      59 (13.1)         25 (13.9)
  2                                      247 (54.9)        102 (56.7)
  3                                      134 (29.8)        47 (26.1)
  4                                      10 (2.2)          6 (3.3)
  Surgical margin, *N* (%)                                 
  Negative                               241 (72.6)        104 (75.4)
  Positive                               91 (27.4)         34 (24.6)
  Biochemical recurrence, *N* (%)        184 (40.2)        90 (48.6)
  Median follow‐up, months               54                74

Abbreviations: IQR, interquartile range; PSA, prostate‐specific antigen.

John Wiley & Sons, Ltd

Of the 18 SNPs in eight cell adhesion molecules analyzed in the discovery set, four SNPs in *CDH2* showed marginal association with BCR (Table [S1](#cam42163-sup-0001){ref-type="supplementary-material"}). After adjusting for age, PSA at diagnosis, pathologic Gleason score, stage, and surgical margin, *CDH2* rs643555 remained significant (*P* = 0.039, Table [2](#cam42163-tbl-0002){ref-type="table"} and Figure [1](#cam42163-fig-0001){ref-type="fig"}A). Consistent with the results of discovery set, *CDH2* rs643555 was found to be associated with BCR in the same direction in an independent replication set (*P* = 0.046, Table [2](#cam42163-tbl-0002){ref-type="table"} and Figure [1](#cam42163-fig-0001){ref-type="fig"}B). In combined analysis, patients with rs643555 TT genotype had a significantly shorter BCR‐free survival compared with those with CC/CT genotypes (adjusted HR 1.78, 95% CI 1.19‐2.67, *P* = 0.005, Table [2](#cam42163-tbl-0002){ref-type="table"} and Figure [1](#cam42163-fig-0001){ref-type="fig"}C).

###### 

SNPs associated with BCR in patients receiving RP

  Gene SNP           Discovery   Replication   Combined                                                                                                      
  ------------------ ----------- ------------- ------------------------- ----------- ----- ---- ------------------------- ----------- ---------------------- -----------
  *CDH2* rs1944294                                                                                                                                           
  AA                 234         97            1.00                                  104   49   1.00                                  1.00                    
  AT                 181         64            0.779 (0.524‐1.158)       0.217       67    31   0.808 (0.434‐1.506)       0.503       0.79 (0.56‐1.10)       0.16
  TT                 39          19            1.477 (0.818‐2.665)       0.196       14    10   **2.430 (1.087‐5.431)**   **0.031**   **1.76 (1.09‐2.83)**   **0.02**
  AT/TT vs AA                                  0.885 (0.614‐1.274)       0.510                  1.040 (0.597‐1.814)       0.889       0.93 (0.68‐1.26)       0.64
  TT vs AA/AT                                  1.641 (0.929‐2.899)       0.088                  **2.640 (1.221‐5.707)**   **0.014**   **1.94 (1.23‐3.07)**   **0.005**
  *CDH2* rs3745045                                                                                                                                           
  TT                 132         57            1.00                                  60    31   1.00                                  1.00                    
  TC                 242         87            0.952 (0.630‐1.437)       0.813       94    37   0.820 (0.424‐1.589)       0.557       0.91 (0.64‐1.30)       0.61
  CC                 82          38            0.955 (0.564‐1.617)       0.864       31    22   2.102 (0.996‐4.435)       0.051       1.24 (0.81‐1.91)       0.33
  TC/CC vs TT                                  0.953 (0.645‐1.406)       0.807                  1.103 (0.607‐2.002)       0.748       1.00 (0.72‐1.38)       0.98
  CC vs TT/TC                                  0.985 (0.620‐1.565)       0.948                  **2.351 (1.219‐4.534)**   **0.011**   1.31 (0.90‐1.92)       0.16
  *CDH2* rs643555                                                                                                                                            
  CC                 207         85            1.00                                  85    41   1.00                                  1.00                    
  CT                 185         64            0.793 (0.524‐1.202)       0.274       83    38   0.949 (0.522‐1.727)       0.865       0.84 (0.60‐1.18)       0.32
  TT                 59          29            1.490 (0.901‐2.462)       0.120       17    11   2.138 (0.943‐4.847)       0.069       **1.65 (1.07‐2.53)**   **0.02**
  CT/TT vs CC                                  0.956 (0.662‐1.381)       0.812                  1.126 (0.647‐1.960)       0.674       1.01 (0.74‐1.37)       0.97
  TT vs CC/CT                                  **1.645 (1.024‐2.642)**   **0.039**              **2.191 (1.015‐4.731)**   **0.046**   **1.78 (1.19‐2.67)**   **0.005**
  *CDH2* rs8084948                                                                                                                                           
  TT                 235         90            1.00                                  126   66   1.00                                  1.00                    
  TA                 98          29            0.690 (0.400‐1.189)       0.182       51    20   0.489 (0.234‐1.022)       0.057       **0.61 (0.39‐0.95)**   **0.03**
  AA                 16          5             0.538 (0.185‐1.566)       0.255       8     4    0.939 (0.325‐2.718)       0.908       0.71 (0.34‐1.51)       0.38
  TA/AA vs TT                                  0.660 (0.395‐1.103)       0.113                  0.573 (0.302‐1.088)       0.089       **0.62 (0.42‐0.93)**   **0.02**
  AA vs TT/TA                                  0.610 (0.212‐1.751)       0.358                  1.123 (0.393‐3.206)       0.829       0.83 (0.39‐1.75)       0.62

HRs were adjusted by age, PSA at diagnosis, pathologic Gleason score, stage, and surgical margin.

*P* \< 0.05 are in boldface.

Abbreviations: BCR, biochemical recurrence; CI, confidence interval; HR, hazard ratio; RP, radical prostatectomy; SNP, single‐nucleotide polymorphism.
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![Kaplan‐Meier survival curves of biochemical recurrence‐free survival according to *CDH2* rs643555 genotypes in (A) discovery set, (B) replication set, and (C) combined analysis. Numbers in parentheses indicate the number of patients](CAM4-8-2777-g001){#cam42163-fig-0001}

According to the functional annotation using HaploReg v4.1, rs643555 is an eQTL for *CDH2*, and is predicted to alter multiple regulatory motifs (Table [S2](#cam42163-sup-0001){ref-type="supplementary-material"}). In eQTL analysis from the GTEx dataset, the risk allele T of rs643555 showed increased *CDH2* expression in transformed human fibroblasts (*P* = 0.026, Figure [2](#cam42163-fig-0002){ref-type="fig"}A). We further investigated the prognostic effects of *CDH2* expression on BCR‐free survival after RP for prostate cancer. Based on the publicly available GSE70769 dataset, high expression of *CDH2* was associated with higher pathologic stages (*P* = 0.043, Figure [2](#cam42163-fig-0002){ref-type="fig"}B) and poorer BCR‐free survival (*P* = 0.005, Figure [2](#cam42163-fig-0002){ref-type="fig"}C).

![Functional analyses of *CDH2* rs643555. A, Association between rs643555 genotypes and *CDH2* expression in transformed human fibroblasts (GTEx dataset). B, *CDH2* is upregulated in advanced prostate cancers (GSE70769 dataset). C, Kaplan‐Meier survival curves of biochemical recurrence‐free survival according to *CDH2* expression levels. Patients were divided at the mean gene expression level into the low and high groups. Numbers in parentheses indicate the number of patients](CAM4-8-2777-g002){#cam42163-fig-0002}

4. DISCUSSION {#cam42163-sec-0008}
=============

In this exploratory study, we investigated associations between genetic variants in eight cancer‐related cell adhesion molecules and prostate cancer prognosis using a two‐stage study design. *CDH2* rs643555 was significantly associated with prostate cancer prognosis in both stages and remained significant after controlling for known risk factors. In addition, rs643555T risk allele was shown to upregulate the expression of *CDH2*, which was then linked to unfavorable BCR‐free survival outcomes, further supporting for the biological plausibility of our findings.

HaploReg identified that *CDH2* rs643555, an intronic variant, may be functional via a direct eQTL regulating the expression of *CDH2*.[16](#cam42163-bib-0016){ref-type="ref"} Several other potential causal variants in the proxy of rs643555 were also predicted to locate in enhancer histone marks and have regulatory effects on *CDH2* through eQTL. According to GTEx dataset, the risk allele T of rs643555 was correlated with increased expression of *CDH2*. CDH2, also known as N‐cadherin, is a transmembrane glycoprotein that mediates calcium‐dependent cell adhesion and is mainly expressed in multiple cell types, including nerve, vascular, myocardial, and mesenchymal cells.[17](#cam42163-bib-0017){ref-type="ref"} Evidence suggests that increased expression of CDH2 together with the loss of E‐cadherin (cadherin switching) plays an essential role during the progression of several human cancers,[18](#cam42163-bib-0018){ref-type="ref"} including prostate cancer.[19](#cam42163-bib-0019){ref-type="ref"} More importantly, aberrant CDH2 expression has been reported, not only in metastatic but also in castration‐resistant prostate cancer.[20](#cam42163-bib-0020){ref-type="ref"} Mechanistic studies demonstrated that CDH2 promotes prostate cancer cells EMT, stemness, and metastatic ability by activating the ErbB signaling pathway.[21](#cam42163-bib-0021){ref-type="ref"} Monoclonal antibodies against CDH2 inhibited androgen‐independent growth, local invasion, and metastasis in castration‐resistant prostate cancer models.[22](#cam42163-bib-0022){ref-type="ref"} Furthermore, a CDH2 antagonist, ADH‐1, is currently being used in clinical trials for treatment of CDH2‐expressing solid tumors.[23](#cam42163-bib-0023){ref-type="ref"} Together, this evidence further supports the hypothesis that CDH2 could be a promising therapeutic target for prostate cancer.

There are some inherent limitations in the present study. First, both study populations are Taiwanese; therefore, our findings may not be generalized to other ethnic groups. Second, we are unable to explore the biological mechanisms behind the SNPs of cell adhesion pathway genes and disease progression because the prostate cancer tissues from study participants were unavailable. Third, we used haplotype‐tagging SNPs to capture most of the genomic diversity, but the linked causal SNPs need to be further identified. Finally, the sample size of both cohorts is relatively small and does not have optimal power for discovering and replicating the associations. We had \>80% power to detect a HR of 1.7 and 1.6 for BCR when assessing a SNP with minor allele frequency of 0.2 and 0.4, respectively, in the discovery set consisted of 458 patients. However, the association between *CDH2* rs643555 and prostate cancer progression was replicated across both sets of the study, which would reduce false‐positive findings. In addition, functional studies support the prognostic value of *CDH2* in prostate cancer. Further independent studies with larger number of patients from other ethnic groups and functional experiments are required to validate our findings.

In conclusion, by using a two‐stage study and bioinformatics analyses, we have identified that rs643555C \> T acts as a risk factor of prostate cancer recurrence through increasing expression of *CDH2*. Our study provides new insights into the genetic variants in cell adhesion pathways underlying disease progression, and may offer a prognostic biomarker to the personalized management of prostate cancer.
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